Bioatla, INC

BioAtla, Inc. held its Annual Meeting of Stockholders on July 16, 2026, where shareholders approved the election of two directors, ratified the appointment of Ernst & Young LLP as independent auditor, and approved executive compensation.

BioAtla, Inc. has filed a certificate of merger to execute a 1-for-50 reverse stock split effective April 6, 2026.

BioAtla's stockholders approved a merger and a 1-for-50 reverse stock split, while the company also implemented retention bonuses for key executives following a year without performance bonuses.

BioAtla announced a significant workforce reduction and a formal process to explore strategic options amidst Nasdaq delisting review and revised investment plans.

BioAtla, Inc. announced that Nasdaq's Listing Council has called for a review of its delisting determination, staying the suspension of trading pending the outcome.

BioAtla, Inc. received a delisting determination from Nasdaq, with trading suspension set for February 10, 2026, due to non-compliance with listing rules.

BioAtla reports Q1 2026 financial results, highlighting a strategic shift, workforce reduction, and a $6.5 million amendment to its Context Therapeutics license agreement.

BioAtla, a clinical-stage biopharmaceutical company, reported a net loss of $15.8 million for Q3 2025 and $49.8 million for the nine months ended September 30, 2025, with management expressing substantial doubt about its ability to continue as a going concern.

BioAtla, a clinical-stage biopharmaceutical company, reported significant losses and a critical cash position, raising substantial doubt about its ability to continue as a going concern, while also facing Nasdaq delisting.

BioAtla, Inc. announces its Q1 2025 financial results, highlighting a net loss of $15.3 million and a corporate restructuring including a 30% workforce reduction.

BioAtla, Inc. reported a net loss of $10.6 million for the third quarter of 2024, with revenue of $11 million driven by a licensing agreement.

BioAtla, a clinical-stage biopharmaceutical company, reported a decrease in operating expenses and a net loss for the second quarter of 2024, while maintaining a sufficient cash position to fund operations for at least the next twelve months.

BioAtla, a clinical-stage biopharmaceutical company, reported substantial net losses and a going concern doubt, leading to a 70% workforce reduction and a formal process to explore strategic options.

BioAtla, a clinical-stage biopharmaceutical company, provides an update on its 2024 financial results and ongoing clinical development programs focused on conditionally active biologics (CABs) for solid tumor cancers.

BioAtla, Inc. details its common stock structure, preferred stock authorization, and anti-takeover provisions in a recent SEC filing.

BioAtla CFO Christian Vasquez reported the withholding of common stock shares to satisfy tax obligations following the vesting of restricted stock units.

BioAtla's Chief Medical Officer, Eric Sievers, was granted 240,000 restricted stock units, increasing his beneficial ownership to 598,705 shares.

BioAtla, Inc. CEO Jay M. Short, PhD, was granted 430,000 restricted stock units, aligning executive incentives with long-term shareholder value.

BioAtla CEO Jay M. Short's recent Form 4 filing details the withholding of 7,728 common shares by the issuer to cover tax obligations related to vested restricted stock units.

BioAtla's Chief Financial Officer, Christian Vasquez, reported a routine disposition of 1,802 common shares for tax withholding purposes related to vested restricted stock units.

BioAtla's former CFO, Richard A. Waldron, had 2,729 shares withheld for tax obligations related to restricted stock unit vesting.

BioAtla, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 16, 2026, to be held virtually, with key proposals including director elections and executive compensation.

BioAtla, Inc. has reconvened its special stockholders meeting on January 26, 2026, to vote on a reverse stock split proposal, following an initial failure to secure sufficient votes.

BioAtla, Inc. has adjourned its special stockholder meeting to January 12, 2026, to allow more time for voting on a proposed reverse stock split.

BioAtla, Inc. calls a Special Meeting to vote on issuing new shares for capital and a reverse stock split to maintain its Nasdaq listing.

BioAtla, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

BioAtla, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.

OPOKA Investment Fund Co has reduced its beneficial ownership in BioAtla, Inc. to 4.8% of common stock, indicating a passive investment stance.

Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., and their affiliates, including Anders Hove, have disclosed a combined beneficial ownership of 8.3% of BioAtla, Inc.'s common stock as a passive investment.

Highbridge Capital Management, LLC has filed an amended Schedule 13G, disclosing a 7.7% beneficial ownership stake in BioAtla, Inc., primarily through warrants.

Opoka Investment Fund Co. has disclosed a 6.1% passive ownership stake in BioAtla, Inc., holding 3,547,787 common shares.

Highbridge Capital Management, LLC has reported a 9.9% beneficial ownership stake in BioAtla, Inc., including shares issuable upon warrant exercise, as of December 31, 2024.

BioAtla, Inc.'s Co-founder, Chairman, and CEO, Jay M. Short, has filed an amended Schedule 13G, disclosing a beneficial ownership of 6.6% of the company's common stock as of December 31, 2024.